| N | uppiementary i abić | e ST. Effects of long-tel | rm иени exposure о | n male rats' liver enzyl | me activities and fatty | / acid ieveis (means ± | : >U, n = IU) |
|----------------------------|--|--|--|--|--|---|-----------------------------|
| Grou | sdr | ALT (U/L) | AST (U/L) | TC (mmol/L) | TG (mr | nol/L) | HDL (mmol/L) |
| U | 11 | 08.53 ± 7.31 | 35.89 ± 3.67 | 4.89 ± 1.46 | 1.89 ± | 0.16 | 1.45 ± 0.26 |
| Σ | -1 | 10.32 ± 15.28 ^b | 37.28 ± 8.15 ^b | 5.32 ± 2.08 | 2.52 ± | 0.87 | 1.54 ± 0.68 |
| т | Ċ. | 40.32 ± 10.18 ^a | 55.79 ± 4.62 ^ª | 6.89 ± 0.36^{a} | 3.24 ± | 0.48 ^a | 2.51 ± 0.3^{a} |
| Note. | $^{a}P < 0.05$ compared | d to group C. ^b P < 0.05 | compared to group | M. C: Control group. | 0 mg/(kg·dav): M: Lo | w-dose DEHP group. | 300 mg/(kg·dav): H: |
| High-dose | DEHP group, 600 n | ng/(kg·day). Abbreviat | ions: DEHP, di (2-eth | All and a second and a second a se | LT, alanine aminotrar | sferase; AST, aspart | ic transaminase; TC, |
| Serum Lota | וו כווטופגופרטו; ויס, וו Subb | rigiyceriae; пис, півіп-(lementary Table S2. В | density lipoprotem. | in positive ESI mode in | n male rats serum (me | an + SD. <i>n</i> = 10) | |
| | | | | | | | |
| Groups | PC [18:1(11Z)/ 18:4(6Z,9Z,12Z,15Z)] | LysoPC (20:0/0:0) | LysoPE (22:0/0:0) | LysoPE (P-18:0/0:0) | LysoPC [20:1(11Z)/0:0] | LysoPC (18:0/0:0) | LysoPC [P-18:1 (92)/0:0] |
| υ | 18.49 ± 9.34 ^c | 32.53 ± 3.08 ^d | 43.92 ± 11.54 ^d | 21.43 ± 2.25 ^d | 165.97 ± 34.73 ^d | 562.56 ± 47.04 ^d | 42.68 ± 3.62 ^d |
| Σ | 14.02 ± 7.67 | 17.99 ± 3.67 ^b | 0.00 ± 0.00^{b} | 16.39 ± 3.68 ^b | 85.83 ± 32.81 ^b | 671.43 ± 49.31^{b} | 49.86 ± 4.44 ^b |
| т | 4.34 ± 1.87^{a} | $19.40 \pm 2.91^{\rm b}$ | $2.56 \pm 5.11^{\rm b}$ | 14.93 ± 2.89 ^b | 72.95 ± 20.26 ^b | 734.41 ± 43.19^{b} | 49.43 ± 3.12 ^b |
| Groups | LysoPC (17:0/0:0) | LysoPC [20:2(11Z,14Z)/0:0] | LysoPE (0:0/20:0) | LysoPC [18:1(112)/0:0] | LysoPC [20:3(52,82,112)/0:0] | LysoPC (16:0/0:0) | |
| U | 180.88 ± 21.71^{d} | 32.40 ± 2.79 ^d | 17.29 ± 9.65^{d} | 329.65 ± 22.54 ^d | 14.99 ± 6.51 | 389.56±30.27 | |
| Σ | 148.41 ± 24.36 ^b | 18.99 ± 3.35 ^b | $5.31 \pm 8.77^{\rm b}$ | 373.64 ± 30.56 ^b | 13.09 ± 14.03 | 409.49 ± 34.57 | |
| т | 127.57 ± 17.42 ^{bc} | $18.71 \pm 2.91^{\rm b}$ | 3.27 ± 7.23 ^b | 457.43 ± 36.45 ^{bd} | 46.65 ± 18.74 ^{bd} | 443.44 ± 31.41^{bc} | |
| Groups | LysoPC [18:2(92,122)/0:0] | LysoPC [20:4(5Z,8Z,11Z,14Z)/0:0] | LysoPC [22:6(4Z,7Z, 10Z,13Z,16Z,19Z)/0:0] | LysoPC [16:1(92)/0:0] | LysoPC [18:3(62,92,122)/0:0] | LysoPC (14:0/0:0) | |
| U | 359.01 ± 38.72 | 369.88 ± 30.86 | 254.88 ± 18.81 | 36.49 ± 5.22 | 6.46 ± 2.49 | 29.08 ± 3.55 ^d | |
| Σ | 389.11 ± 18.13 | 454.28 ± 45.03 ^b | 267.34 ± 24.39 | 35.33 ± 6.22 | 8.23 ± 2.11 | 21.13 ± 3.40^{b} | |
| н | 491.28 ± 32.61 ^{bd} | 494.82 ± 43.44 ^{bc} | 225.10 ± 27.92 ^{ad} | 55.71 ± 12.16^{bd} | 13.56 ± 3.32^{bd} | 28.67 ± 4.64 ^d | |
| Groups | Linoelaidylcarnitine | 21-Hydroxypregnenolone | Tetracosahexaenoic acid | Cervonoyl ethanolamide | Indoleacrylic acid | Creatine | |
| U | 20.64 ± 6.07 | 14.74 ± 7.95 | 11.22 ± 4.63 | 44.66 ± 10.08^{d} | 108.38 ± 5.45 | 19.91 ± 2.32 | |
| Σ | 15.32 ± 4.12 | 10.83 ± 6.04 | 9.29 ± 10.27 | 12.50 ± 10.78^{b} | 93.05 ± 14.22 | 18.99 ± 2.73 | |
| н | 7.64 ± 1.65 ^{bd} | 3.37 ± 1.94^{bd} | 2.74 ± 1.02 ^{bc} | 3.81 ± 3.32 ^b | 86.48 ± 6.73 ^b | 14.33 ± 1.54 ^{bd} | |
| Note. 0 mg/kg; M | ^a P < 0.05 comparec 1: Low-dose group, ŝ | d to group C. ^b <i>P</i> < 0.01 300 mg/kg; H: High-do: | compared to group (se group, 600 mg/kg | C. ^c <i>P</i> < 0.05 compared . DEHP, di (2-ethylhex) | to group M. ^d <i>P</i> < 0.01 /l) phthalate; ESI, elec | compared to group trospray ionization. | M. C: Control group, |

Biomed Environ Sci, 2021; 34(11): S1-S4



Supplementary Figure S1. (A) Long-term DEHP exposure induced changes in rats' body weight (BW) at each time point. (B) The DEHP exposure levels in male rats' fat and serum at 6 months (means \pm SD, μ g/g). (C) Long-term DEHP exposure induced alterations of organ/body weight ratio in male rats' liver at 6 month. (D) Altered mRNA expression of liver UDPGT, D1, and CYP2B1 revealed by real-time quantitative PCR. Control: Control group, 0 mg/(kg·day); Low: Low-dose DEHP group, 300 mg/(kg·day); High: High-dose DEHP group, 600 mg/(kg·day). Each data point represents mean \pm standard deviation (SD). **P* < 0.05, ***P* < 0.01 compared to the control group. Abbreviations: DEHP, di-(2-ethylhexyl) phthalate. UDPGT, Uridine diphosphate glucuronic acid transferase; CYP2B1, Cytochrome P450 2B1; D1, Cyclin D1.



Supplementary Figure S2. Long-term DEHP exposure altered histopathology in livers of male rats at 6 months. (A) Control group, 0 mg/(kg·day); (B) Low-dose DEHP group, 300 mg/(kg·day); (C) High-dose DEHP group, 600 mg/(kg·day). HE stain magnification, 200×. Yellow arrow: fat vacuoles; Blue arrow: inflammatory cell infiltration; Red arrow: hepatocellular injury. DEHP, di-(2-ethylhexyl) phthalate.



Supplementary Figure S3. Representative positive mode BPI and TIC chromatograms of serum from the control (A) and high-dose DEHP (B) groups at month 6 using UPLC/ESI-Q-TOF/MS. BPI, base peak intensity; TIC, total ions chromatogram; ES+, positive ion mode. DEHP, di-(2-ethylhexyl) phthalate. Control group, 0 mg/(kg·day); High-dose DEHP group, 600 mg/(kg·day).



Supplementary Figure S4. Chemical structure and mass fragment information of representative serum biomarkers identified in this study with different collision energy (ev). (A), LysoPC [18:2(9Z, 12Z)/0:0] (25ev). (B), The mass spectra of LysoPC [18:2(9Z, 12Z)/0:0] from the authentic standard (25ev). (C), LysoPC [20:3(5Z, 8Z, 11Z)/0:0] (20ev). (D), The mass spectra of LysoPC [20:3(5Z, 8Z, 11Z)/0:0] from the authentic standard (25ev). (E), LysoPC [18:3(6Z, 9Z, 12Z)/0:0] (10ev). (F), The mass spectra of LysoPC [18:3(6Z, 9Z, 12Z)/0:0] from the authentic standard (15ev). (G), LysoPC [20:4(5Z, 8Z, 11Z, 14Z)/0:0] (15ev). (H), The mass spectra of [20:4(5Z, 8Z, 11Z, 14Z)/0:0] from the authentic standard (20ev).